Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address major under-treated health issues, including alcohol use disorder [5][6] - The company has a robust intellectual property portfolio consisting of eighteen patent families and 27 granted patents, with plans to seek additional patents as needed [2] Product Development - Clearmind's proprietary MEAI-based alcohol substitute beverage program has advanced, with patents granted in the U.S., India, and Europe [2] - The company is in the final stages of a pre-clinical study required for a novel-food application submission, complying with global regulations for novel foods and food additives [4] Market Insights - The no- and low-alcohol consumption market, which accounts for approximately 70% of global volumes, grew by 5% in volume in 2023, reaching a market value of over $13 billion [5] - The no/low alcohol category is projected to grow at a compound annual growth rate (CAGR) of 6% from 2023 to 2027 [5]